Names | |
---|---|
Preferred IUPAC name
1-(3-{4-[(piperidin-1-yl)methyl]phenoxy}propyl)piperidine | |
Identifiers | |
3D model (
JSmol)
|
|
Abbreviations | JNJ-5207852 |
ChEMBL | |
ChemSpider | |
MeSH | JNJ-5207852 |
PubChem
CID
|
|
UNII | |
CompTox Dashboard (
EPA)
|
|
| |
| |
Properties | |
C20H32N2O | |
Molar mass | 316.480 g/mol |
Except where otherwise noted, data are given for materials in their
standard state (at 25 °C [77 °F], 100 kPa).
|
JNJ-5207852 is a histamine antagonist selective for the H3 subtype. It has stimulant and nootropic effects in animal studies, [1] and has been suggested as a possible treatment for some memory defects associated with epilepsy. [2] JNJ-5207852 itself did not progress to clinical development due to poor pharmacokinetic characteristics, but the related compound JNJ-17216498 was in a Phase II clinical trial for the treatment of narcolepsy in 2007. [3]
Names | |
---|---|
Preferred IUPAC name
1-(3-{4-[(piperidin-1-yl)methyl]phenoxy}propyl)piperidine | |
Identifiers | |
3D model (
JSmol)
|
|
Abbreviations | JNJ-5207852 |
ChEMBL | |
ChemSpider | |
MeSH | JNJ-5207852 |
PubChem
CID
|
|
UNII | |
CompTox Dashboard (
EPA)
|
|
| |
| |
Properties | |
C20H32N2O | |
Molar mass | 316.480 g/mol |
Except where otherwise noted, data are given for materials in their
standard state (at 25 °C [77 °F], 100 kPa).
|
JNJ-5207852 is a histamine antagonist selective for the H3 subtype. It has stimulant and nootropic effects in animal studies, [1] and has been suggested as a possible treatment for some memory defects associated with epilepsy. [2] JNJ-5207852 itself did not progress to clinical development due to poor pharmacokinetic characteristics, but the related compound JNJ-17216498 was in a Phase II clinical trial for the treatment of narcolepsy in 2007. [3]